Suppr超能文献

横纹肌瘤易感综合征:相关儿童恶性肿瘤治疗与预后的历史回顾

Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies.

作者信息

Andres Sarah, Huang Karen, Shatara Margaret, Abdelbaki Mohamed S, Ranalli Mark, Finlay Jonathan, Gupta Ajay

机构信息

Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA.

The Division of Hematology and Oncology, St. Louis Children's Hospital, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

出版信息

Pediatr Blood Cancer. 2024 Jun;71(6):e30979. doi: 10.1002/pbc.30979. Epub 2024 Mar 30.

Abstract

Rhabdoid tumor predisposition syndrome (RTPS) is a rare disorder associated with malignant rhabdoid tumor of the kidney (RTK), atypical teratoid rhabdoid tumor (ATRT), and/or other extracranial, extrarenal rhabdoid tumors (EERT), and these pediatric malignancies are difficult to treat. Presently, most of the information regarding clinical manifestations, treatment, and outcomes of rhabdoid tumors comes from large data registries and case series. Our current understanding of treatments for patients with rhabdoid tumors may inform how we approach patients with RTPS. In this manuscript, we review the genetic and clinical features of RTPS and, using known registry data and clinical reports, review associated tumor types ATRT, RTK, and EERT, closing with potential new approaches to treatment. We propose collaborative international efforts to study the use of SMARC (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin)-targeting agents, high-dose consolidative therapy, and age-based irradiation of disease sites in RTPS.

摘要

横纹肌样瘤易感综合征(RTPS)是一种罕见的疾病,与肾恶性横纹肌样瘤(RTK)、非典型畸胎样横纹肌样瘤(ATRT)和/或其他颅外、肾外横纹肌样瘤(EERT)相关,而这些儿童恶性肿瘤难以治疗。目前,关于横纹肌样瘤临床表现、治疗和预后的大多数信息来自大型数据登记库和病例系列。我们目前对横纹肌样瘤患者治疗方法的理解可能会为我们治疗RTPS患者提供思路。在本手稿中,我们回顾了RTPS的遗传和临床特征,并利用已知的登记数据和临床报告,回顾了相关肿瘤类型ATRT、RTK和EERT,最后介绍了潜在的新治疗方法。我们提议开展国际合作,研究使用针对SMARC(与SWI/SNF相关、基质相关、肌动蛋白依赖性染色质调节因子)的药物、高剂量巩固治疗以及对RTPS疾病部位进行基于年龄的放疗。

相似文献

1
Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies.
Pediatr Blood Cancer. 2024 Jun;71(6):e30979. doi: 10.1002/pbc.30979. Epub 2024 Mar 30.
3
Rhabdoid tumor: the Irish experience 1986-2013.
Cancer Genet. 2014 Sep;207(9):398-402. doi: 10.1016/j.cancergen.2014.05.015. Epub 2014 Jun 11.
8
Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
Eur J Pediatr. 2024 Feb;183(2):557-567. doi: 10.1007/s00431-023-05345-x. Epub 2023 Nov 29.
10
Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges.
Expert Rev Anticancer Ther. 2005 Oct;5(5):907-15. doi: 10.1586/14737140.5.5.907.

引用本文的文献

1
Small-Molecule Drugs in Pediatric Neuro-Oncology.
Curr Oncol. 2025 Jul 25;32(8):417. doi: 10.3390/curroncol32080417.
3
Diagnostic challenge of malignant rhabdoid tumor presenting as a forehead mass in an infant: A case report.
Int J Surg Case Rep. 2025 Jun;131:111372. doi: 10.1016/j.ijscr.2025.111372. Epub 2025 Apr 25.
4
Rhabdoid Tumor Predisposition Syndrome : A Comprehensive Review of Genetics, Clinical Manifestations, and Management.
J Korean Neurosurg Soc. 2025 May;68(3):311-320. doi: 10.3340/jkns.2025.0014. Epub 2025 Mar 27.
5
Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome.
Neurooncol Adv. 2024 Sep 12;6(1):vdae158. doi: 10.1093/noajnl/vdae158. eCollection 2024 Jan-Dec.

本文引用的文献

1
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110.
2
Current Molecular and Clinical Landscape of ATRT - The Link to Future Therapies.
Cancer Manag Res. 2023 Dec 7;15:1369-1393. doi: 10.2147/CMAR.S379451. eCollection 2023.
3
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.
Biochem Pharmacol. 2023 Sep;215:115727. doi: 10.1016/j.bcp.2023.115727. Epub 2023 Aug 2.
5
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
Pediatr Blood Cancer. 2023 Aug;70(8):e30422. doi: 10.1002/pbc.30422. Epub 2023 May 23.
6
SMARCB1/INI1-deficient undifferentiated pancreatic carcinoma in a 13-year-old male patient: A case report.
Pediatr Blood Cancer. 2023 Mar;70(3):e30038. doi: 10.1002/pbc.30038. Epub 2022 Nov 1.
7
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations.
Gynecol Oncol Rep. 2022 Oct 6;44:101077. doi: 10.1016/j.gore.2022.101077. eCollection 2022 Dec.
8
[Analysis of 18 cases of malignant rhabdoid tumor in children].
Zhonghua Er Ke Za Zhi. 2022 Sep 2;60(9):908-914. doi: 10.3760/cma.j.cn112140-20220323-00241.
9
Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement.
Front Oncol. 2022 Jul 13;12:932337. doi: 10.3389/fonc.2022.932337. eCollection 2022.
10
SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities.
Cancers (Basel). 2022 Jul 27;14(15):3645. doi: 10.3390/cancers14153645.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验